Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:I-135-I-143
doi: 10.1161/CIRCULATIONAHA.104.525436
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, K. A.
Right arrow Articles by Badylak, S. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, K. A.
Right arrow Articles by Badylak, S. F.
Related Collections
Right arrow Other myocardial biology
Right arrow Other heart failure
Right arrow Animal models of human disease
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy
Right arrow CV surgery: other

(Circulation. 2005;112:I-135 – I-143.)
© 2005 American Heart Association, Inc.


Cell Transplantation and Tissue Engineering

Extracellular Matrix Scaffold for Cardiac Repair

Keith A. Robinson, PhD; Jinshen Li, MD, PhD; Megumi Mathison, MD, PhD; Alka Redkar, PhD; Jianhua Cui, MD; Nicolas A.F. Chronos, MD; Robert G. Matheny, MD; Stephen F. Badylak, DVM, PhD, MD

From the American Cardiovascular Research Institute (K.A.R., J.L., M.M., A.R., J.C., N.A.F.C., R.G.M.), Norcross, Ga; Cardiac Surgical Associates, PC (R.G.M.), Atlanta, Ga; and McGowan Institute of Regenerative Medicine (S.F.B.), Pittsburgh, Pa.

Correspondence to Dr Keith A. Robinson, 3155 Northwoods Place, Norcross, GA 30071. E-mail krobinson{at}acrionline.org

Background— Heart failure remains a significant problem. Tissue-engineered cardiac patches offer potential to treat severe heart failure. We studied an extracellular matrix scaffold for repairing the infarcted left ventricle.

Methods and Results— Pigs (n=42) underwent left ventricular (LV) infarction. At 6 to 8 weeks, either 4-layer multilaminate urinary bladder-derived extracellular matrix or expanded polytetrafluoroethlyene (ePTFE) was implanted as full-thickness LV wall patch replacement. At 1-week, 1-month, or 3-month intervals, pigs were terminated. After macroscopic examination, samples of tissue were prepared for histology, immunocytochemistry, and analysis of cell proportions by flow cytometry. One-week and 1-month patches were intact with thrombus and inflammation; at 1 month, there was also tissue with spindle-shaped cells in proteoglycan-rich and collagenous matrix. More {alpha}-smooth muscle actin-positive cells were present in urinary bladder matrix (UBM) than in ePTFE (22.2±3.3% versus 8.4±2.7%; P=0.04). At 3 months, UBM was bioresorbed, and a collagen-rich vascularized tissue with numerous myofibroblasts was present. Isolated regions of {alpha}-sarcomeric actin-positive, intensely {alpha}-smooth muscle actin-immunopositive, and striated cells were observed. ePTFE at 3 months had foreign-body response with necrosis and calcification. Flow cytometry showed similarities of cells from UBM to normal myocardium, whereas ePTFE had limited cardiomyocyte markers.

Conclusions— Appearance of a fibrocellular tissue that included contractile cells accompanied biodegradation of UBM when implanted as an LV-free wall infarction patch. UBM appears superior to synthetic material for cardiac patching and trends toward myocardial replacement at 3 months.


Key Words: heart failure • surgery • tissue engineering